Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Epigenetics | Review

An immunotherapeutic approach to decipher the role of long non-coding RNAs in cancer progression, resistance and epigenetic regulation of immune cells

Authors: Krishnapriya M. Varier, Hemavathi Dhandapani, Wuling Liu, Jialei Song, Chunlin Wang, Anling Hu, Yaacov Ben-David, Xiangchun Shen, Yanmei Li, Babu Gajendran

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Immunotherapeutic treatments are gaining attention due to their effective anti-tumor response. Particularly, the revolution of immune checkpoint inhibitors (ICIs) produces promising outcomes for various cancer types. However, the usage of immunotherapy is limited due to its low response rate, suggesting that tumor cells escape the immune surveillance. Rapid advances in transcriptomic profiling have led to recognize immune-related long non-coding RNAs (LncRNAs), as regulators of immune cell-specific gene expression that mediates immune stimulatory as well as suppression of immune response, indicating LncRNAs as targets to improve the efficacy of immunotherapy against tumours. Moreover, the immune-related LncRNAs acting as epigenetic modifiers are also under deep investigation. Thus, herein, is a summarised knowledge of LncRNAs and their regulation in the adaptive and innate immune system, considering their importance in autophagy and predicting putative immunotherapeutic responses.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, et al. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017;81:116–29. https://doi.org/10.1016/j.ejca.2017.01.035.CrossRefPubMed

Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018;9:245. https://doi.org/10.3389/fphar.2018.00245.CrossRefPubMedPubMedCentral

Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T, et al. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019;7(1):129. https://doi.org/10.1186/s40425-019-0594-0.CrossRefPubMedPubMedCentral

Papaioannou NE, Beniata OV, Vitsos P, Tsitsilonis O, Samara P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4(14):261. https://doi.org/10.21037/atm.2016.04.01.CrossRefPubMedPubMedCentral

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014;5(24):12472–508. https://doi.org/10.18632/oncotarget.2998.CrossRefPubMedPubMedCentral

Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol. 2005;175(3):1373–81. https://doi.org/10.4049/jimmunol.175.3.1373.CrossRefPubMed

Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Current challenges in cancer treatment. Clin Ther. 2016;38(7):1551–66. https://doi.org/10.1016/j.clinthera.2016.03.026.CrossRefPubMed

Kakimi K, Karasaki T, Matsushita H, Sugie T. Advances in personalized cancer immunotherapy. Breast Cancer. 2017;24(1):16–24. https://doi.org/10.1007/s12282-016-0688-1.CrossRefPubMed

Sambi M, Bagheri L, Szewczuk MR. Current challenges in cancer immunotherapy: Multimodal approaches to improve efficacy and patient response rates. J Oncol. 2019;2019:4508794. https://doi.org/10.1155/2019/4508794.

10.

Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020;30(6):507–19. https://doi.org/10.1038/s41422-020-0337-2.CrossRefPubMedPubMedCentral

11.

Mpekris F, Voutouri C, Baish JW, Duda DG, Munn LL, Stylianopoulos T, et al. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc Natl Acad Sci U S A. 2020;117(7):3728–37. https://doi.org/10.1073/pnas.1919764117.CrossRefPubMedPubMedCentral

12.

Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193(3):651–69. https://doi.org/10.1534/genetics.112.146704.CrossRefPubMedPubMedCentral

13.

Denaro N, Merlano MC, Lo NC. Long noncoding RNAs as regulators of cancer immunity. Mol Oncol. 2019;13(1):61–73. https://doi.org/10.1002/1878-0261.12413.CrossRefPubMed

14.

Stein LD. Human genome: end of the beginning. Nature. 2004;431(7011):915–6. https://doi.org/10.1038/431915a.CrossRefPubMed

15.

Sonkoly E, Ståhle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol. 2008;18(2):131–40. https://doi.org/10.1016/j.semcancer.2008.01.005.CrossRefPubMed

16.

Lee HM, Nguyen DT, Lu LF. Progress and challenge of microRNA research in immunity. Front Genet. 2014;5:178. https://doi.org/10.3389/fgene.2014.00178.CrossRefPubMedPubMedCentral

17.

Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118. https://doi.org/10.1038/s41580-020-00315-9.CrossRefPubMed

18.

Connerty P, Lock RB, de Bock CE. Long Non-coding RNAs: Major regulators of cell stress in cancer. Front Oncol. 2020;10:285. https://doi.org/10.3389/fonc.2020.00285.CrossRefPubMedPubMedCentral

19.

Tuck AC, Tollervey D. A transcriptome-wide atlas of RNP composition reveals diverse classes of mRNAs and lncRNAs. Cell. 2013;154(5):996–1009. https://doi.org/10.1016/j.cell.2013.07.047.CrossRefPubMedPubMedCentral

20.

Cipolla GA, de Oliveira JC, Salviano-Silva A, Lobo-Alves SC, Lemos DS, Oliveira LC, et al. Long non-coding RNAs in multifactorial diseases: Another layer of complexity. noncoding RNA. 2018;4(2):13. https://doi.org/10.3390/ncrna4020013.CrossRefPubMedCentral

21.

Wang KC, Chang HY. Molecular Mechanisms of Long Noncoding RNAs. Mol Cell. 2011;43(6):904–14 https://doi.org/10.1016/j.molcel.2011.08.018.CrossRefPubMedPubMedCentral

22.

Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2013;73(3):1180–9. https://doi.org/10.1158/0008-5472.CAN-12-2850.CrossRefPubMed

23.

Qu D, Sun WW, Li L, Ma L, Sun L, Jin X, et al. Long noncoding RNA MALAT1 releases epigenetic silencing of HIV-1 replication by displacing the polycomb repressive complex 2 from binding to the LTR promoter. Nucleic Acids Res. 2019;47(6):3013–27. https://doi.org/10.1093/nar/gkz117.CrossRefPubMedPubMedCentral

24.

Satpathy AT, Chang HY. Long noncoding RNA in hematopoiesis and immunity. Immunity. 2015;42(5):792–804. https://doi.org/10.1016/j.immuni.2015.05.004.CrossRefPubMed

25.

Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010;125(2):S33–40. https://doi.org/10.1016/j.jaci.2009.09.017.CrossRefPubMed

26.

Katz SG, Rabinovich PM. T Cell Reprogramming Against Cancer. Methods Mol Biol. 2020;2097:3–44. https://doi.org/10.1007/978-1-0716-0203-4_1.CrossRefPubMedPubMedCentral

27.

Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21(22):5047–56. https://doi.org/10.1158/1078-0432.CCR-15-0685.CrossRefPubMed

28.

Luo Y, Yang J, Yu J, Liu X, Yu C, Hu J, et al. Long non-coding RNAs: Emerging roles in the immunosuppressive tumor microenvironment. Front Oncol. 2020;10:48. https://doi.org/10.3389/fonc.2020.00048.CrossRefPubMedPubMedCentral

29.

Zhang L, Xu X, Su X. Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application. Mol Cancer. 2020;19(1):48. https://doi.org/10.1186/s12943-020-01154-0.CrossRefPubMedPubMedCentral

30.

Pan LJ, Zhong TF, Tang RX, Li P, Dang YW, Huang SN, et al. Upregulation and clinicopathological significance of long non-coding NEAT1 RNA in NSCLC tissues. Asian Pac J Cancer Prev. 2015;16(7):2851–5. https://doi.org/10.7314/apjcp.2015.16.7.2851.CrossRefPubMed

31.

Peng W, Wang Z, Fan H. LncRNA NEAT1 impacts cell proliferation and apoptosis of colorectal cancer via regulation of Akt signaling. Pathol Oncol Res. 2017;23(3):651–6. https://doi.org/10.1007/s12253-016-0172-4.CrossRefPubMed

32.

Yan K, Fu Y, Zhu N, Wang Z, Hong JL, Li Y, et al. Repression of lncRNA NEAT1 enhances the antitumor activity of CD8⁺T cells against hepatocellular carcinoma via regulating miR-155/Tim-3. Int J Biochem Cell Biol. 2019;110:1–8. https://doi.org/10.1016/j.biocel.2019.01.019.CrossRefPubMed

33.

Ji J, Yin Y, Ju H, Xu X, Liu W, Fu Q, et al. Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. Cell Death Dis. 2018;9(5):478. https://doi.org/10.1038/s41419-018-0528-7.CrossRefPubMedPubMedCentral

34.

Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19(10):1112–25. https://doi.org/10.1038/s41590-018-0207-y.CrossRefPubMed

35.

Vigneau S, Rohrlich PS, Brahic M, Bureau JF. Tmevpg1, a candidate gene for the control of Theiler's virus persistence, could be implicated in the regulation of gamma interferon. J Virol. 2003;77(10):5632–8. https://doi.org/10.1128/jvi.77.10.5632-5638.2003.CrossRefPubMedPubMedCentral

36.

Collier SP, Henderson MA, Tossberg JT, Aune TM. Regulation of the Th1 genomic locus from Ifng through Tmevpg1 by T-bet. J Immunol. 2014;193(8):3959–65. https://doi.org/10.4049/jimmunol.1401099.CrossRefPubMed

37.

Gomez JA, Wapinski OL, Yang YW, Bureau JF, Gopinath S, Monack DM, et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-γ locus. Cell. 2013;152(4):743–54. https://doi.org/10.1016/j.cell.2013.01.015.CrossRefPubMedPubMedCentral

38.

Ahmad I, Valverde A, Ahmad F, Naqvi AR. Long noncoding RNA in myeloid and lymphoid cell differentiation, polarization and function. Cells. 2020;9(2):269. https://doi.org/10.3390/cells9020269.CrossRefPubMedCentral

39.

Ranzani V, Rossetti G, Panzeri I, Arrigoni A, Bonnal RJ, Curti S, et al. The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nat Immunol. 2015;16(3):318–25. https://doi.org/10.1038/ni.3093.CrossRefPubMedPubMedCentral

40.

Badalamenti G, Fanale D, Incorvaia L, Barraco N, Listì A, Maragliano R, et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? Cell Immunol. 2019;343:103753. https://doi.org/10.1016/j.cellimm.2018.01.013.CrossRefPubMed

41.

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35:S185–98. https://doi.org/10.1016/j.semcancer.2015.03.004.CrossRefPubMed

42.

Jiang R, Tang J, Chen Y, Deng L, Ji J, Xie Y, et al. The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion. Nat Commun. 2017;8:15129. https://doi.org/10.1038/ncomms15129.CrossRefPubMedPubMedCentral

43.

Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016;22(6):679–84. https://doi.org/10.1038/nm.4086.CrossRefPubMed

44.

Zemmour D, Pratama A, Loughhead SM, Mathis D, Benoist C. Flicr, a long noncoding RNA, modulates Foxp3 expression and autoimmunity. Proc Natl Acad Sci U S A. 2017;114(17):E3472–80. https://doi.org/10.1073/pnas.1700946114.CrossRefPubMedPubMedCentral

45.

Pei X, Wang X, Li H. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. Int J Biol Macromol. 2018;118(Pt A):24–30. https://doi.org/10.1016/j.ijbiomac.2018.06.033.CrossRefPubMed

46.

Zhang M, Wang W, Li T, Yu X, Zhu Y, Ding F, et al. Long noncoding RNA SNHG1 predicts a poor prognosis and promotes hepatocellular carcinoma tumorigenesis. Biomed Pharmacother. 2016;80:73–9. https://doi.org/10.1016/j.biopha.2016.02.036.CrossRefPubMed

47.

Wang L, Ye S, Wang J, Gu Z, Zhang Y, Zhang C, et al. HuR stabilizes lnc-Sox5 mRNA to promote tongue carcinogenesis. Biochemistry (Mosc). 2017;82(4):438–45. https://doi.org/10.1134/S0006297917040046.CrossRef

48.

Zhang Y, Liao G, Bai J, Zhang X, Xu L, Deng C, et al. Identifying cancer driver lncRNAs bridged by functional effectors through integrating multi-omics data in human cancers. Mol Ther Nucleic Acids. 2019;17:362–73. https://doi.org/10.1016/j.omtn.2019.05.030.CrossRefPubMedPubMedCentral

49.

Zhou WY, Zhang MM, Liu C, Kang Y, Wang JO, Yang XH. Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p. J Cell Physiol. 2019;234(12):23176–89. https://doi.org/10.1002/jcp.28884.CrossRefPubMed

50.

Kathuria H, Millien G, McNally L, Gower AC, Tagne JB, Cao Y, et al. NKX2-1-AS1 negatively regulates CD274/PD-L1, cell-cell interaction genes, and limits human lung carcinoma cell migration. Sci Rep. 2018;8(1):14418. https://doi.org/10.1038/s41598-018-32793-5.CrossRefPubMedPubMedCentral

51.

Zhang C, Jiang F, Su C, Xie P, Xu L. Upregulation of long noncoding RNA SNHG20 promotes cell growth and metastasis in esophageal squamous cell carcinoma via modulating ATM-JAK-PD-L1 pathway. J Cell Biochem. 2019. https://doi.org/10.1002/jcb.28444.

52.

Zhang J, Fan D, Jian Z, Chen GG, Lai PB. Cancer specific long noncoding RNAs show differential expression patterns and competing endogenous RNA potential in hepatocellular carcinoma. PLoS One. 2015;10(10):e0141042. https://doi.org/10.1371/journal.pone.0141042.CrossRefPubMedPubMedCentral

53.

Yao K, Wang Q, Jia J, Zhao H. A competing endogenous RNA network identifies novel mRNA, miRNA and lncRNA markers for the prognosis of diabetic pancreatic cancer. Tumour Biol. 2017;39(6):1010428317707882. https://doi.org/10.1177/1010428317707882.CrossRefPubMed

54.

Liu X, Huang G, Zhang J, Zhang L, Liang Z. Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis. PLoS One. 2020;15(10):e0240321. https://doi.org/10.1371/journal.pone.0240321.CrossRefPubMedPubMedCentral

55.

Hanly DJ, Esteller M, Berdasco M. Interplay between long non-coding RNAs and epigenetic machinery: emerging targets in cancer? Philos Trans R Soc Lond Ser B Biol Sci. 2018;373(1748):20170074. https://doi.org/10.1098/rstb.2017.0074.CrossRef

56.

Zhao G, Su Z, Song D, Mao Y, Mao X. The long noncoding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF-κB. FEBS Lett. 2016;590(17):2884–95. https://doi.org/10.1002/1873-3468.12315.CrossRefPubMed

57.

Wang QM, Lian GY, Song Y, Huang YF, Gong Y. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. Life Sci. 2019;231:116335. https://doi.org/10.1016/j.lfs.2019.03.040.CrossRefPubMed

58.

Ron Y, De Baetselier P, Gordon J, Feldman M, Segal S. Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. Eur J Immunol. 1981;11(12):964–8. https://doi.org/10.1002/eji.1830111203.CrossRefPubMed

59.

Petri A, Dybkær K, Bøgsted M, Thrue CA, Hagedorn PH, Schmitz A, et al. Long noncoding RNA expression during human B-cell development. PLoS One. 2015;10(9):e0138236. https://doi.org/10.1371/journal.pone.0138236.CrossRefPubMedPubMedCentral

60.

Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, et al. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia. 2014;28(12):2376–87. https://doi.org/10.1038/leu.2014.126.CrossRefPubMedPubMedCentral

61.

Zhou SW, Su BB, Zhou Y. Expression of FAS-AS1 in breast cancer and its effect on the host gene sFas. Zhonghua Yi Xue Za Zhi. 2016;96(12):949–53. https://doi.org/10.3760/cma.j.issn.0376-2491.2016.12.009.CrossRefPubMed

62.

Zhou W, Liu T, Saren G, Liao L, Fang W, Zhao H. Comprehensive analysis of differentially expressed long non-coding RNAs in non-small cell lung cancer. Oncol Lett. 2019;18(2):1145–56. https://doi.org/10.3892/ol.2019.10414.CrossRefPubMedPubMedCentral

63.

Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28–40. https://doi.org/10.1016/j.ccr.2009.11.019.CrossRefPubMed

64.

Ishii N, Ozaki K, Sato H, Mizuno H. Susumu Saito, Takahashi A, et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. J Hum Genet. 2006;51(12):1087–99. https://doi.org/10.1007/s10038-006-0070-9.CrossRefPubMed

65.

Sheik Mohamed J, Gaughwin PM, Lim B, Robson P, Lipovich L. Conserved long noncoding RNAs transcriptionally regulated by Oct4 and Nanog modulate pluripotency in mouse embryonic stem cells. RNA. 2010;16(2):324–37. https://doi.org/10.1261/rna.1441510.CrossRefPubMedPubMedCentral

66.

Sattari A, Siddiqui H, Moshiri F, Ngankeu A, Nakamura T, Kipps TJ, et al. Upregulation of long noncoding RNA MIAT in aggressive form of chronic lymphocytic leukemias. Oncotarget. 2016;7(34):54174–82. https://doi.org/10.18632/oncotarget.11099.CrossRefPubMedPubMedCentral

67.

Wang LQ, Wong KY, Li ZH, Chim CS. Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. Oncotarget. 2016;7(50):82400–10. https://doi.org/10.18632/oncotarget.12252.CrossRefPubMedPubMedCentral

68.

Park SM, Park SJ, Kim HJ, Kwon OH, Kang TW, Sohn HA, et al. A known expressed sequence tag, BM742401, is a potent lincRNA inhibiting cancer metastasis. Exp Mol Med. 2013;45(7):e31. https://doi.org/10.1038/emm.2013.59.CrossRefPubMedPubMedCentral

69.

Cho SF, Chang YC, Chang CS, Lin SF, Liu YC, Hsiao HH, et al. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer. 2014;14:809. https://doi.org/10.1186/1471-2407-14-809.CrossRefPubMedPubMedCentral

70.

Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 2018;18(4):e27. https://doi.org/10.4110/in.2018.18.e27.CrossRefPubMedPubMedCentral

71.

Fang P, Xiang L, Chen W, Li S, Huang S, Li J, et al. LncRNA GAS5 enhanced the killing effect of NK cell on liver cancer through regulating miR-544/RUNX3. Innate Immun. 2019;25(2):99–109. https://doi.org/10.1177/1753425919827632.CrossRefPubMedPubMedCentral

72.

Baytak E, Gong Q, Akman B, Yuan H, Chan WC, Küçük C. Whole transcriptome analysis reveals dysregulated oncogenic lncRNAs in natural killer/T-cell lymphoma and establishes MIR155HG as a target of PRDM1. Tumour Biol. 2017;39(5):1010428317701648. https://doi.org/10.1177/1010428317701648.CrossRefPubMed

73.

Askarian-Amiri ME, Crawford J, French JD, Smart CE, Smith MA, Clark MB, et al. SNORD-host RNA Zfas1 is a regulator of mammary development and a potential marker for breast cancer. RNA. 2011;17(5):878–91. https://doi.org/10.1261/rna.2528811.CrossRefPubMedPubMedCentral

74.

Mei M, Zhang M. Non-coding RNAs in natural killer/T-cell lymphoma. Front Oncol. 2019;9:515. https://doi.org/10.3389/fonc.2019.00515.CrossRefPubMedPubMedCentral

75.

Zhu L, Zhang X, Fu X, Li Z, Sun Z, Wu J, et al. c-Myc mediated upregulation of long noncoding RNA SNHG12 regulates proliferation and drug sensitivity in natural killer/T-cell lymphoma. J Cell Biochem. 2019;120(8):12628–37. https://doi.org/10.1002/jcb.28529.CrossRefPubMed

76.

Ma Y, Zhang C, Zhang B, Yu H, Yu Q. circRNA of AR-suppressed PABPC1 91 bp enhances the cytotoxicity of natural killer cells against hepatocellular carcinoma via upregulating UL16 binding protein 1. Oncol Lett. 2019;17(1):388–97. https://doi.org/10.3892/ol.2018.9606.CrossRefPubMed

77.

Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity. 2014;41(1):21–35. https://doi.org/10.1016/j.immuni.2014.06.013.CrossRefPubMedPubMedCentral

78.

Italiani P, Boraschi D. From monocytes to M1/M2 macrophages: Phenotypical vs. functional differentiation. Front Immunol. 2014;5:514. https://doi.org/10.3389/fimmu.2014.00514.CrossRefPubMedPubMedCentral

79.

Ye Y, Xu Y, Lai Y, He W, Li Y, Wang R, et al. Long non-coding RNA cox-2 prevents immune evasion and metastasis of hepatocellular carcinoma by altering M1/M2 macrophage polarization. J Cell Biochem. 2018;119(3):2951–63. https://doi.org/10.1002/jcb.26509.CrossRefPubMed

80.

Zhang Y, Feng J, Fu H, Liu C, Yu Z, Sun Y, et al. Coagulation factor X regulated by CASC2c recruited macrophages and induced M2 polarization in glioblastoma multiforme. Front Immunol. 2018;9:1557. https://doi.org/10.3389/fimmu.2018.01557.CrossRefPubMedPubMedCentral

81.

Liang ZX, Liu HS, Wang FW, Xiong L, Zhou C, Hu T, et al. LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization. Cell Death Dis. 2019;10(11):829. https://doi.org/10.1038/s41419-019-2077-0.CrossRefPubMedPubMedCentral

82.

Li X, Lei Y, Wu M, Li N. Regulation of macrophage activation and polarization by HCC-derived exosomal lncRNA TUC339. Int J Mol Sci. 2018;19(10):2958. https://doi.org/10.3390/ijms19102958.CrossRefPubMedCentral

83.

Cao J, Dong R, Jiang L, Gong Y, Yuan M, You J, et al. LncRNA-MM2P identified as a modulator of macrophage M2 polarization. Cancer Immunol Res. 2019;7(2):292–305. https://doi.org/10.1158/2326-6066.CIR-18-0145.CrossRefPubMed

84.

Chen S, Shao C, Xu M, Ji J, Xie Y, Lei Y, et al. Macrophage infiltration promotes invasiveness of breast cancer cells via activating long non-coding RNA UCA1. Int J Clin Exp Pathol. 2015;8(8):9052–61.PubMedPubMedCentral

85.

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, et al. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016;1(2):e85841. https://doi.org/10.1172/jci.insight.85841.CrossRefPubMedCentral

86.

Chen C, He W, Huang J, Wang B, Li H, Cai Q, et al. LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nat Commun. 2018;9(1):3826. https://doi.org/10.1038/s41467-018-06152-x.CrossRefPubMedPubMedCentral

87.

Leija Montoya G, González Ramírez J, Sandoval Basilio J, Serafín Higuera I, Isiordia Espinoza M, González González R, et al. Long non-coding RNAs: Regulators of the activity of myeloid-derived suppressor cells. Front Immunol. 2019;10:1734. https://doi.org/10.3389/fimmu.2019.01734.CrossRefPubMedPubMedCentral

88.

Liu J, Ding D, Jiang Z, Du T, Liu J, Kong Z. Long non-coding RNA CCAT1/miR-148a/PKCζ prevents cell migration of prostate cancer by altering macrophage polarization. Prostate. 2019;79(1):105–12. https://doi.org/10.1002/pros.23716.CrossRefPubMed

89.

Zhou YX, Zhao W, Mao LW, Wang YL, Xia LQ, Cao M, et al. Long non-coding RNA NIFK-AS1 inhibits M2 polarization of macrophages in endometrial cancer through targeting miR-146a. Int J Biochem Cell Biol. 2018;104:25–33. https://doi.org/10.1016/j.biocel.2018.08.017.CrossRefPubMed

90.

Kong F, Deng X, Kong X, Du Y, Li L, Zhu H, et al. ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. Oncogene. 2018;37(45):5982–96. https://doi.org/10.1038/s41388-018-0387-9.CrossRefPubMedPubMedCentral

91.

Rajabinejad M, Salari F, Gorgin Karaji A, Rezaiemanesh A. The role of myeloid-derived suppressor cells in the pathogenesis of rheumatoid arthritis; anti- or pro-inflammatory cells? Artif Cells Nanomed Biotechnol. 2019;47(1):4149–58. https://doi.org/10.1080/21691401.2019.1687504.CrossRefPubMed

92.

Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3):162–74. https://doi.org/10.1038/nri2506.CrossRefPubMedPubMedCentral

93.

Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020;9(3):561. https://doi.org/10.3390/cells9030561.CrossRefPubMedCentral

94.

Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021:1–14. https://doi.org/10.1038/s41577-020-00490-y.

95.

Hatziioannou A, Alissafi T, Verginis P. Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the force. J Leukoc Biol. 2017;102(2):407–21. https://doi.org/10.1189/jlb.5VMR1116-493R.CrossRefPubMed

96.

Ma P, Beatty PL, McKolanis J, Brand R, Schoen RE, Finn OJ. Circulating myeloid derived suppressor cells (MDSC) that Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Front Immunol. 2019;10:1401. https://doi.org/10.3389/fimmu.2019.01401.CrossRefPubMedPubMedCentral

97.

Shang W, Gao Y, Tang Z, Zhang Y, Yang R. The pseudogene Olfr29-ps1 promotes the suppressive function and differentiation of monocytic MDSCs. Cancer Immunol Res. 2019;7(5):813–27. https://doi.org/10.1158/2326-6066.CIR-18-0443.CrossRefPubMed

98.

Gao Y, Wang T, Li Y, Zhang Y, Yang R. Lnc-chop promotes immunosuppressive function of myeloid-derived suppressor cells in tumor and inflammatory environments. J Immunol. 2018;200(8):2603–14. https://doi.org/10.4049/jimmunol.1701721.CrossRefPubMed

99.

Shang W, Tang Z, Gao Y, Qi H, Su X, Zhang Y, et al. LncRNA RNCR3 promotes Chop expression by sponging miR-185-5p during MDSC differentiation. Oncotarget. 2017;8(67):111754–69. https://doi.org/10.18632/oncotarget.22906.CrossRefPubMedPubMedCentral

100.

Tian X, Ma J, Wang T, Tian J, Zheng Y, Peng R, et al. Long non-coding RNA RUNXOR accelerates MDSC-mediated immunosuppression in lung cancer. BMC Cancer. 2018;18(1):660. https://doi.org/10.1186/s12885-018-4564-6.CrossRefPubMedPubMedCentral

101.

Zheng Y, Tian X, Wang T, Xia X, Cao F, Tian J, et al. Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Mol Cancer. 2019;18(1):61. https://doi.org/10.1186/s12943-019-0978-2.CrossRefPubMedPubMedCentral

102.

Tian X, Zheng Y, Yin K, Ma J, Tian J, Zhang Y, et al. LncRNA AK036396 inhibits maturation and accelerates immunosuppression of polymorphonuclear myeloid-derived suppressor cells by enhancing the stability of Ficolin B. Cancer Immunol Res. 2020;8(4):565–77. https://doi.org/10.1158/2326-6066.CIR-19-0595.CrossRefPubMed

103.

Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–41. https://doi.org/10.1016/j.cell.2011.10.026.CrossRefPubMed

104.

Kirkegaard K, Taylor MP, Jackson WT. Cellular autophagy: surrender, avoidance and subversion by microorganisms. Nat Rev Microbiol. 2004;2(4):301–14. https://doi.org/10.1038/nrmicro865.CrossRefPubMedPubMedCentral

105.

Nardacci R, Ciccosanti F, Marsella C, Ippolito G, Piacentini M, Fimia GM. Role of autophagy in HIV infection and pathogenesis. J Intern Med. 2017;281(5):422–32. https://doi.org/10.1111/joim.12596.CrossRefPubMed

106.

Jiang GM, Tan Y, Wang H, Peng L, Chen HT, Meng XJ, et al. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Mol Cancer. 2019;18(1):17. https://doi.org/10.1186/s12943-019-0944-z.CrossRefPubMedPubMedCentral

107.

Yao H, Han B, Zhang Y, Shen L, Huang R. Non-coding RNAs and Autophagy. Adv Exp Med Biol. 2019;1206:199–220. https://doi.org/10.1007/978-981-15-0602-4_10.CrossRefPubMed

108.

Yang L, Wang H, Shen Q, Feng L, Jin H. Long non-coding RNAs involved in autophagy regulation. Cell Death Dis. 2017;8(10):e3073. https://doi.org/10.1038/cddis.2017.464.CrossRefPubMedPubMedCentral

109.

Xue Z, Zhang Z, Liu H, Li W, Guo X, Zhang Z, et al. lincRNA-Cox2 regulates NLRP3 inflammasome and autophagy mediated neuroinflammation. Cell Death Differ. 2019;26(1):130–45. https://doi.org/10.1038/s41418-018-0105-8.CrossRefPubMed

110.

Li Z, Li J, Tang N. Long noncoding RNA Malat1 is a potent autophagy inducer protecting brain microvascular endothelial cells against oxygen-glucose deprivation/reoxygenation-induced injury by sponging miR-26b and upregulating ULK2 expression. Neuroscience. 2017;354:1–10. https://doi.org/10.1016/j.neuroscience.2017.04.017.CrossRefPubMed

111.

Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G, Zhu YS. MALAT1: a potential biomarker in cancer. Cancer Manag Res. 2018;10:6757–68. https://doi.org/10.2147/CMAR.S169406.CrossRefPubMedPubMedCentral

112.

Fu Z, Luo W, Wang J, Peng T, Sun G, Shi J, et al. Malat1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STMN1, RAB5A and ATG4D expression in glioma. Biochem Biophys Res Commun. 2017;492(3):480–6. https://doi.org/10.1016/j.bbrc.2017.08.070.CrossRefPubMed

113.

Chen ZH, Wang WT, Huang W, Fang K, Sun YM, Liu SR, et al. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ. 2017;24(2):212–24. https://doi.org/10.1038/cdd.2016.111.CrossRefPubMed

114.

Yu Y, Zhang W, Li A, Chen Y, Ou Q, He Z, et al. Association of long noncoding RNA biomarkers with clinical immune subtype and prediction of immunotherapy response in patients with cancer. JAMA Netw Open. 2020;3(4):e202149. https://doi.org/10.1001/jamanetworkopen.2020.2149.CrossRefPubMedPubMedCentral

115.

Song B, Guan Z, Liu F, Sun D, Wang K, Qu H. Long non-coding RNA HOTAIR promotes HLA-G expression via inhibiting miR-152 in gastric cancer cells. Biochem Biophys Res Commun. 2015;464(3):807–13. https://doi.org/10.1016/j.bbrc.2015.07.040.CrossRefPubMed

116.

Osses DF, Roobol MJ, Schoots IG. Prediction medicine: Biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis. Int J Mol Sci. 2019;20(7):1637. https://doi.org/10.3390/ijms20071637.CrossRefPubMedCentral

117.

Sartori DA, Chan DW. Biomarkers in prostate cancer: what’s new? Curr Opin Oncol. 2014;26(3):259–64. https://doi.org/10.1097/CCO.0000000000000065.CrossRefPubMedPubMedCentral

118.

Zhang R, Xia Y, Wang Z, Zheng J, Chen Y, Li X, et al. Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer. Biochem Biophys Res Commun. 2017;490(2):406–14. https://doi.org/10.1016/j.bbrc.2017.06.055 Epub 2017 Jun 13. PMID: 28623135.CrossRefPubMed

119.

Subhash S, Andersson PO, Kosalai ST, Kanduri C, Kanduri M. Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL. Clin Epigenetics. 2016;8:106. https://doi.org/10.1186/s13148-016-0274-6.CrossRefPubMedPubMedCentral

120.

Guo G, Kang Q, Zhu X, Chen Q, Wang X, Chen Y, et al. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. Oncogene. 2015;34(14):1768–79. https://doi.org/10.1038/onc.2014.131.CrossRefPubMed

121.

Chen L, Wang W, Cao L, Li Z, Wang X. Long non-coding RNA CCAT1 acts as a competing endogenous RNA to regulate cell growth and differentiation in acute myeloid leukemia. Mol Cell. 2016;39(4):330–6. https://doi.org/10.14348/molcells.2016.2308.CrossRef

122.

Hirano T, Yoshikawa R, Harada H, Harada Y, Ishida A, Yamazaki T. Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression. Mol Cancer. 2015;14:90. https://doi.org/10.1186/s12943-015-0364-7.CrossRefPubMedPubMedCentral

123.

Wang XQ, Crutchley JL, Dostie J. Shaping the genome with non-coding RNAs. Curr Genomics. 2011;12(5):307–21. https://doi.org/10.2174/138920211796429772.CrossRefPubMedPubMedCentral

124.

Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, et al. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res. 2009;315(17):2941–52. https://doi.org/10.1016/j.yexcr.2009.07.001.CrossRefPubMed

125.

Kasar S, Underbayev C, Yuan Y, Hanlon M, Aly S, Khan H, et al. Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene. 2014;33(25):3307–15. https://doi.org/10.1038/onc.2013.291.CrossRefPubMed

126.

Morenos L, Chatterton Z, Ng JL, Halemba MS, Parkinson-Bates M, Mechinaud F, et al. Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. Mol Cancer. 2014;13:123. https://doi.org/10.1186/1476-4598-13-123.CrossRefPubMedPubMedCentral

127.

Mertens D, Philippen A, Ruppel M, Allegra D, Bhattacharya N, Tschuch C, et al. Chronic lymphocytic leukemia and 13q14: miRs and more. Leuk Lymphoma. 2009;50(3):502–5. https://doi.org/10.1080/10428190902763509.CrossRefPubMed

128.

Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of origin and genetic alterations in the pathogenesis of multiple myeloma. Front Immunol. 2019;10:1121. https://doi.org/10.3389/fimmu.2019.01121.CrossRefPubMedPubMedCentral

129.

Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB, et al. Long noncoding RNAs in mouse embryonic stem cell pluripotency and differentiation. Genome Res. 2008;18(9):1433–45. https://doi.org/10.1101/gr.078378.108.CrossRefPubMedPubMedCentral

130.

Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 2009;28(2):195–208. https://doi.org/10.1038/onc.2008.373.CrossRefPubMed

131.

Nakamura Y, Takahashi N, Kakegawa E, Yoshida K, Ito Y, Kayano H, et al. The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma. Cancer Genet Cytogenet. 2008;182(2):144–9. https://doi.org/10.1016/j.cancergencyto.2008.01.013 PMID: 18406879.CrossRefPubMed

132.

Mourtada-Maarabouni M, Williams GT. Role of GAS5 noncoding RNA in mediating the effects of rapamycin and its analogues on mantle cell lymphoma cells. Clin Lymphoma Myeloma Leuk. 2014;14(6):468–73. https://doi.org/10.1016/j.clml.2014.02.011 Epub 2014 Mar 3. PMID: 24703244.CrossRefPubMed

133.

Zhang YY, Huang SH, Zhou HR, Chen CJ, Tian LH, Shen JZ. Role of HOTAIR in the diagnosis and prognosis of acute leukemia. Oncol Rep. 2016;36(6):3113–22. https://doi.org/10.3892/or.2016.5147.CrossRefPubMedPubMedCentral

134.

Oh EJ, Kim SH, Yang WI, Ko YH, Yoon SO. Long non-coding RNA HOTAIR expression in diffuse large B-cell lymphoma: In relation to polycomb repressive complex pathway proteins and H3K27 trimethylation. J Pathol Transl Med. 2016;50(5):369–76. https://doi.org/10.4132/jptm.2016.06.06.CrossRefPubMedPubMedCentral

135.

Yan Y, Han J, Li Z, Yang H, Sui Y, Wang M. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. Mol Med Rep. 2016;13(6):5125–31. https://doi.org/10.3892/mmr.2016.5190.CrossRefPubMedPubMedCentral

136.

Wang XQ, Dostie J. Reciprocal regulation of chromatin state and architecture by HOTAIRM1 contributes to temporal collinear HOXA gene activation. Nucleic Acids Res. 2017;45(3):1091–104. https://doi.org/10.1093/nar/gkw966.CrossRefPubMed

137.

Zhao H, Zhang X, Frazão JB, Condino-Neto A, Newburger PE. HOX antisense lincRNA HOXA-AS2 is an apoptosis repressor in all trans retinoic acid treated NB4 promyelocytic leukemia cells. J Cell Biochem. 2013;114(10):2375–83. https://doi.org/10.1002/jcb.24586.CrossRefPubMedPubMedCentral

138.

Peng W, Wu J, Feng J. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma. Biomed Pharmacother. 2016;79:188–93. https://doi.org/10.1016/j.biopha.2016.02.032.CrossRefPubMed

139.

Mangiavacchi A, Sorci M, Masciarelli S, Larivera S, Legnini I, Iosue I, et al. The miR-223 host non-coding transcript linc-223 induces IRF4 expression in acute myeloid leukemia by acting as a competing endogenous RNA. Oncotarget. 2016;7(37):60155–68. https://doi.org/10.18632/oncotarget.11165.CrossRefPubMedPubMedCentral

140.

Ghazavi F, De Moerloose B, Van Loocke W, Wallaert A, Helsmoortel HH, Ferster A, et al. Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Oncotarget. 2016;7(45):73769–80. https://doi.org/10.18632/oncotarget.12063.CrossRefPubMedPubMedCentral

141.

Conde L, Riby J, Zhang J, Bracci PM, Skibola CF. Copy number variation analysis on a non-Hodgkin lymphoma case-control study identifies an 11q25 duplication associated with diffuse large B-cell lymphoma. PLoS One. 2014;9(8):e105382. https://doi.org/10.1371/journal.pone.0105382.CrossRefPubMedPubMedCentral

142.

Trimarchi T, Bilal E, Ntziachristos P, Fabbri G, Dalla-Favera R, Tsirigos A, et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 2014;158(3):593–606. https://doi.org/10.1016/j.cell.2014.05.049.CrossRefPubMedPubMedCentral

143.

Peng W, Feng J. Long noncoding RNA LUNAR1 associates with cell proliferation and predicts a poor prognosis in diffuse large B-cell lymphoma. Biomed Pharmacother. 2016;77:65–71. https://doi.org/10.1016/j.biopha.2015.12.001.CrossRefPubMed

144.

Benetatos L, Hatzimichael E, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2010;34(2):148–53. https://doi.org/10.1016/j.leukres.2009.06.019.CrossRefPubMed

145.

Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 2003;88(11):5119–26. https://doi.org/10.1210/jc.2003-030222.CrossRefPubMed

146.

Zhuang W, Ge X, Yang S, Huang M, Zhuang W, Chen P, et al. Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription. Stem Cells. 2015;33(6):1985–97. https://doi.org/10.1002/stem.1989.CrossRefPubMed

147.

Doose G, Haake A, Bernhart SH, López C, Duggimpudi S, Wojciech F, et al. MINCR is a MYC-induced lncRNA able to modulate MYC’s transcriptional network in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 2015;112(38):E5261–70. https://doi.org/10.1073/pnas.1505753112.CrossRefPubMedPubMedCentral

148.

Emmrich S, Streltsov A, Schmidt F, Thangapandi VR, Reinhardt D, Klusmann JH. LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. Mol Cancer. 2014;13:171. https://doi.org/10.1186/1476-4598-13-171.CrossRefPubMedPubMedCentral

149.

Wang Y, Wu P, Lin R, Rong L, Xue Y, Fang Y. LncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia. Sci Rep. 2015;5:13749. https://doi.org/10.1038/srep13749.CrossRefPubMedPubMedCentral

150.

Gao C, Zhang J, Wang Q, Ren C. Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemia. Oncol Lett. 2016;12(2):1051–7. https://doi.org/10.3892/ol.2016.4738.CrossRefPubMedPubMedCentral

151.

Zeng C, Yu X, Lai J, Yang L, Chen S, Li Y. Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia. J Hematol Oncol. 2015;8:126. https://doi.org/10.1186/s13045-015-0223-4.CrossRefPubMedPubMedCentral

152.

Nagoshi H, Taki T, Hanamura I, Nitta M, Otsuki T, Nishida K, et al. Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer Res. 2012;72(19):4954–62. https://doi.org/10.1158/0008-5472.CAN-12-0213.CrossRefPubMed

153.

Carramusa L, Contino F, Ferro A, Minafra L, Perconti G, Giallongo A, et al. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol. 2007;213(2):511–8. https://doi.org/10.1002/jcp.21133.CrossRefPubMed

154.

Enciso-Mora V, Broderick P, Ma Y, Jarrett RF, Hjalgrim H, Hemminki K, et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nat Genet. 2010;42(12):1126–30. https://doi.org/10.1038/ng.696.CrossRefPubMedPubMedCentral

155.

Graham M, Adams JM. Chromosome 8 breakpoint far 3’ of the c-myc oncogene in a Burkitt’s lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus. EMBO J. 1986;5(11):2845–51.CrossRefPubMedPubMedCentral

156.

Shtivelman E, Henglein B, Groitl P, Lipp M, Bishop JM. Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma. Proc Natl Acad Sci U S A. 1989;86(9):3257–60. https://doi.org/10.1073/pnas.86.9.3257.CrossRefPubMedPubMedCentral

157.

Tsutsumi Y, Chinen Y, Sakamoto N, Nagoshi H, Nishida K, Kobayashi S, et al. Deletion or methylation of CDKN2A/2B and PVT1 rearrangement occur frequently in highly aggressive B-cell lymphomas harboring 8q24 abnormality. Leuk Lymphoma. 2013;54(12):2760–4. https://doi.org/10.3109/10428194.2013.790543.CrossRefPubMed

158.

Tanaka R, Satoh H, Moriyama M, Satoh K, Morishita Y, Yoshida S, et al. Intronic U50 small-nucleolar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. Genes Cells. 2000;5(4):277–87. https://doi.org/10.1046/j.1365-2443.2000.00325.x.CrossRefPubMed

159.

Zhang L, Xu HG, Lu C. A novel long non-coding RNA T-ALL-R-LncR1 knockdown and Par-4 cooperate to induce cellular apoptosis in T-cell acute lymphoblastic leukemia cells. Leuk Lymphoma. 2014;55(6):1373–82. https://doi.org/10.3109/10428194.2013.829574.CrossRefPubMed

160.

Saitou M, Sugimoto J, Hatakeyama T, Russo G, Isobe M. Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia. Oncogene. 2000;19(23):2796–802. https://doi.org/10.1038/sj.onc.1203604.CrossRefPubMed

161.

Wong KY, Li Z, Zhang X, Leung GK, Chan GC, Chim CS. Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Mol Cancer. 2015;14:175. https://doi.org/10.1186/s12943-015-0444-8.CrossRefPubMedPubMedCentral

162.

Coccaro N, Zagaria A, Tota G, Anelli L, Orsini P, Casieri P, et al. Overexpression of the LSAMP and TUSC7 genes in acute myeloid leukemia following microdeletion/duplication of chromosome 3. Cancer Genet. 2015;208(10):517–22. https://doi.org/10.1016/j.cancergen.2015.07.006.CrossRefPubMed

163.

Hughes JM, Legnini I, Salvatori B, Masciarelli S, Marchioni M, Fazi F, et al. C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia. Oncotarget. 2015;6(21):18534–44. https://doi.org/10.18632/oncotarget.4069.CrossRefPubMedPubMedCentral

164.

Plass C, Yu F, Yu L, Strout MP, El-Rifai W, Elonen E, et al. Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene. 1999;18(20):3159–65. https://doi.org/10.1038/sj.onc.1202651.CrossRefPubMed

165.

Dallosso AR, Hancock AL, Malik S, Salpekar A, King-Underwood L, Pritchard-Jones K, et al. Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer. RNA. 2007;13(12):2287–99. https://doi.org/10.1261/rna.562907.CrossRefPubMedPubMedCentral

166.

Zeng MN, Ma WL. Zheng WL, Bioinformatics analysis of microRNA comprehensive regulatory network in B- cell acute lymphoblastic leukemia. 2016;37(7):585–90. https://doi.org/10.3760/cma.j.issn.0253-2727.2016.07.009.

167.

The LncRNA and Disease Database. http://www.cuilab.cn/lncrnadisease.

Title: An immunotherapeutic approach to decipher the role of long non-coding RNAs in cancer progression, resistance and epigenetic regulation of immune cells
Authors: Krishnapriya M. Varier
Hemavathi Dhandapani
Wuling Liu
Jialei Song
Chunlin Wang
Anling Hu
Yaacov Ben-David
Xiangchun Shen
Yanmei Li
Babu Gajendran
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Epigenetics
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-01997-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors

Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer

Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer

An SETD1A/Wnt/β-catenin feedback loop promotes NSCLC development

ESCO2 promotes lung adenocarcinoma progression by regulating hnRNPA1 acetylation

ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling

Keynote webinar | Spotlight on antibody–drug conjugates in cancer